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ABSTRACT 
Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 
(PLOSL), also known as Nasu-Hakola disease, is a recessively inherited disease of 
brain and bone. PLOSL manifests as early-onset progressive dementia and bone 
fractures. Mutations in the TYROBP (DAP12) and TREM2 genes have been 
identified as the primary cause of PLOSL. DAP12 and TREM2 encode important 
signalling molecules in cells of the innate immune system. The mechanism by which 
loss-of-function of the DAP12/TREM2 signalling complex leads to PLOSL is 
currently unknown.  
The aim of this thesis work was to gain insight into the pathogenic mechanisms 
behind PLOSL. To first identify the central nervous system (CNS) cell types that 
express both Dap12 and Trem2, the expression patterns of Dap12 and Trem2 in 
mouse CNS were analyzed. Dap12 and Trem2 expression was seen from embryonic 
stage to adulthood and microglial cells and oligodendrocytes were identified as the 
major Dap12/Trem2 producing cells of the CNS. To subsequently identify the 
pathways and biological processes associated with DAP12/TREM2 mediated 
signalling in human cells, genome wide transcript analysis of in vitro differentiated 
dendritic cells (DCs) of PLOSL patients representing functional knockouts of either 
DAP12 or TREM2 was performed. Both DAP12 and TREM2 deficient cells 
differentiated into DCs and responded to pathogenic stimuli. However, the DCs 
showed morphological differences compared to control cells due to defects in the 
  
actin filaments. Transcript profiles of the patient DCs showed differential expression 
of genes involved in immune response and for genes earlier associated with other 
disorders of the CNS as well as genes involved in the remodeling of bone, linking 
the findings with the tissue phenotype of PLOSL patients. To analyze the effect of 
Dap12 deficiency in the CNS, genome wide expression analysis of Dap12 deficient 
mouse brain and Dap12 deficient microglia as well as functional analysis of Dap12 
deficient microglia was performed. Regulation of several pathways involved in 
synaptic function and transcripts coding for the myelin components was seen in 
Dap12 knockout mice. Decreased migration, morphological changes and shortened 
lifespan of the Dap12 knockout microglia was further observed.  
Taken together, this thesis work showed that both Dap12 and Trem2 are expressed 
by CNS microglia and that Dap12 deficiency results in functional defects of these 
cells. Lack of Dap12 in the CNS also leads to synaptic abnormalities even before 
pathological changes are seen in the tissue level.This work further showed that loss-
of-function of DAP12 or TREM2 leads to changes in morphology and gene 
expression in human dendritic cells. These data underline the functional diversity of 
the molecules of the innate immune system and implies their significant contribution 
also in demyelinating CNS disorders, including those resulting in dementia.  
 
Keywords: PLOSL, Nasu-Hakola disease, neurodegeneration, DAP12, TREM2, 
innate immunity, dendritic cells, microglia 
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TIIVISTELMÄ 
Polykystinen lipomembranoottinen osteodysplasia ja sklerosoiva leukoenkefalopatia 
(PLOSL) on autosomissa peittyvästi periytyvä luuston ja aivojen sairaus. PLOSL:sta 
käytetään myös nimeä Nasu-Hakolan tauti. PLOSL aiheuttaa luuston heikkenemistä 
ja varhaisella iällä alkavan dementian. Mutaatiot TYROBP (DAP12) ja TREM2 
geeneissä johtavat PLOSL:n. DAP12 ja TREM2 proteiinit ovat tärkeitä 
immuunijärjestelmän solujen signaalinvälityksessä. Mekanismi, jolla 
DAP12/TREM2 välitteisten signaalien puute johtaa PLOSL:n, on kuitenkin 
selvittämättä. 
Tämän väitöskirjatutkimuksen tavoitteena oli selvittää PLOSL:n tautimekanismeja. 
Aluksi tarkasteltiin Dap12 ja Trem2 lähetti RNA:n ja proteiinien ilmentymistä hiiren 
keskushermostossa. Molempia ilmennettiin samoilla aivoalueilla sikiökaudelta 
lähtien aina aikuisuuteen saakka. Mikrogliat ja oligodendrosyytit tunnistettiin Dap12 
ja Trem2 ilmentäviksi keskushermoston solutyypeiksi. Seuraavaksi haluttiin 
selvittää mihin aineenvaihduntareitteihin ja solun toimintoihin DAP12 ja TREM2 
puutos vaikuttaa ihmisen soluissa. Tätä tutkittiin genominlaajuisella 
ekspressioanalyysillä DAP12 ja TREM2 mutanteissa potilaiden dendriittisoluissa. 
Potilaiden dendriittisolut erilaistuivat ja reagoivat patogeenistimulaatioon lähes 
normaalisti. Solujen morfologiassa nähtiin kuitenkin muutoksia johtuen solujen 
tukirangan aktiinin epänormaalista järjestäytymisestä. Ekspressioanalyysissä nähtiin 
eroja sekä immuunipuolustukseen liittyvien geenien että keskushermostosairauksiin 
  
ja luun muodostukseen liittyvien geenien ilmentymisessä potilaiden ja kontrollien 
välillä. Seuraavaksi tarkasteltiin Dap12 puutoksen seurauksia hiiren 
keskushermostossa genominlaajuisen ekspressioanalyysin avulla. Geenien 
ilmentymistä analysoitiin Dap12 poistogeenisten hiirten aivoissa ja mikroglia-
soluissa. Aivoista eristetyillä mikroglia-soluilla tehtiin myös toiminnallisia kokeita. 
Synapsien toimintaan ja myeliinin muodostukseen liittyvien geenien ilmentymisessä 
nähtiin eroja Dap12 poistogeenisten ja kontrollihiirten aivoissa. Dap12 
poistogeeniset mikroglia-solut liikkuivat huonommin ja kuolivat aikaisemmin kuin 
villityypin mikrogliat. 
Tässä väitöskirjatyössä havaittiin että mikrogliat ilmentävät Dap12:ta ja Trem2:ta 
keskushermostossa ja että Dap12:n puute johtaa mikrogliojen vialliseen toimintaan. 
Dap12:n puute aivoissa johtaa myös muutoksiin synapsien toimintaan liittyvien 
geenien ilmentymisessä jo ennen kuin aivoissa nähdään muutoksia kudostasolla. 
DAP12:n ja TREM2:n puute johtaa lisäksi morfologisiin ja geenien ilmentymisen 
muutoksiin ihmisen dendriittisoluissa. Tutkimuksen tulokset korostavat 
synnynnäiseen immuniteettiin liittyvien molekyylien toiminnan monimuotoisuutta ja 
viittaavat siihen, että niillä olisi tärkeä rooli myös keskushermostoa rappeuttavissa 
sairauksissa. 
 
Avansanat: PLOSL, Nasu-Hakolan tauti, keskushermoston rappeutuminen, DAP12, 
TREM2, synnynnäinen immuniteetti, dendriittisolu, mikroglia 
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ABBREVIATIONS 
AD Alzheimer’s disease 
AMPA alpha-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid 
APC  antigen presenting cell 
BBB  blood brain barrier 
BDNF  brain derived neurotrophic factor 
BMDM  bone marrow derived macrophages 
BM-MC  bone marrow derived myeloid cells 
bp  base pair 
CCL  CC chemokine ligand 
CCR  CC chemokine receptor 
CD  cluster of differentiation 
CNS  central nervous system 
DAP12  DNAX activation protein of 12 kDa 
DC  dendritic cell 
EAE  experimental autoimmune encephalomyelitis 
ELISA  enzyme-linked immunosorbent assay 
ERK  extracellular signal-regulated kinase 
ES cell  embryonic stem cell 
FcR  Fc receptor 
FTD  frontotemporal dementia 
GABA  gamma-aminobutyric acid 
GFAP  glial fibrillary acidic protein 
GM-CSF  granulocyte-macrophage colony stimulating factor 
GO  gene ontology 
HE  hematoxylin-eosin 
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HIV human immunodeficiency virus 
HLA human leukocyte antigen 
IFN interferon 
Ig immunoglobulin 
IL interleukin 
ITAM intracellular tyrosine based activation motif 
ITIM intracellular tyrosine based inhibitory motif 
KARAP killer cell activating receptor-associated protein 
kb kilobase 
kDa kilo Dalton 
KIR killer cell inhibitory receptor 
LPS  lipopolysaccharide 
LTP  long-term potentiation 
mAb  monoclonal antibody 
MBP  myelin basic protein 
M-CSF  macrophage colony stimulating factor 
MHC  major histocompatibility complex 
mIPSC  miniature inhibitory postsynaptic current 
MOG  myelin oligodendrocyte glycoprotein 
mRNA  messenger RNA 
MS  multiple sclerosis 
NF-κB  nuclear factor kappa B 
NK cell  natural killer cell 
NKR  natural killer receptor 
NMDA  N-methyl-D-aspartic acid 
NMDAR  NMDA receptor 
NO  nitric oxide 
PBMC  peripheral blood mononuclear cells 
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PCR  polymerase chain reaction 
PLOSL polycystic lipomembranous osteodysplasia with 
sclerosing leukoencephalopathy 
PTK protein tyrosine kinase 
RANKL receptor activator of NF-κB ligand 
RT-PCR reverse transcriptase-PCR 
SAPK stress-activated protein kinase 
SNP single nucleotide polymorphism 
Syk spleen tyrosine kinase 
TLR Toll like receptor 
TNF  tumor necrosis factor 
TREM  triggering receptor expressed on myeloid cells 
TrkB  tyrosine kinase receptor B 
TYROBP  TYRO protein tyrosine kinase binding protein 
ZAP-70  zeta-associated protein of 70 kDa 
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1 INTRODUCTION 
Diseases of the central nervous system (CNS), especially dementia, become more 
common in aging populations. They thus present increasing medical, social, and 
financial challenge to the society. Both, genetic and environmental factors, 
contribute to the complex process of neurodegeneration. Understanding the disease 
mechanisms is essential in developing treatments or helping to prevent these 
diseases. We have currently more means and experience in studying monogenic than 
complex diseases. In addition to being interesting at their own right, monogenic 
diseases can serve as models for understanding the pathogenic mechanisms of more 
common disorders.  
Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 
(PLOSL) is a recessively inherited disease, which causes early onset progressive 
dementia and bone fractures. Molecular basis of PLOSL is known, since mutations in 
DAP12 and TREM2 have been identified as the primary cause of the disease (Paloneva 
et al. 2000; Paloneva et al. 2002). Together, DAP12 and TREM2 form a signalling 
receptor complex in cells of the myeloid lineage (Bouchon et al. 2001b; Daws et al. 
2001). Microglia and osteoclasts are the myeloid cells of the brain and bone, 
respectively, suggesting their involvement in PLOSL pathogenesis. The mechanism 
by which loss of DAP12/TREM2 mediated signalling in myeloid cells leads to the 
dementia and neurodegeneration observed in PLOSL is currently not known. 
Animal models are important tools for studying disease mechanisms, especially in 
the CNS where tissue samples from patients at early stages of the disease are not 
readily available. Cell models, especially patient cells, are also valuable for 
analyzing the cellular processes affected by disease causing mutations. Novel high-
throughput methods, such as genome wide expression analysis, have made it 
possible to analyse these models more efficiently than before.  
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The aim of this thesis work was to gain insight into the pathogenic mechanisms 
behind PLOSL. To achieve this goal, expression of Dap12 and Trem2 in the 
developing mouse CNS as well as in primary cells derived from the CNS was first 
analyzed both in RNA and protein level. Next, the genome-wide gene expression 
patterns as well as functional responses of cells collected from PLOSL patients 
homozygous for loss-of-function mutations of DAP12 or TREM2 and those of 
Dap12 knockout mice were analyzed. 
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2 REVIEW OF THE LITERATURE 
2.1 Dementia 
Dementia is defined as “the development of multiple cognitive deficits that include 
memory impairment and at least one of the following cognitive disturbances: 
aphasia, apraxia, agnosia or a disturbance in executive functioning. The cognitive 
deficits must be sufficiently severe to cause impairment in the occupational or social 
functioning and must represent a decline from a previously higher level of 
functioning” (American Psychiatric Association 1994). Dementia is a complex 
clinical phenotype with multiple causes. Dementia can be caused by primary 
neurodegenerative disorders, such as Alzheimers’s disease, frontotemporal 
dementias, dementia with Lewy bodies, Parkinson’s disease, and Huntington’s 
disease; vascular diseases, such as familial amyloid angiopathy, and cerebral 
autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
(CADASIL); immunological disorders, such as HIV-dementia and prion disorders; 
toxic and metabolic disorders, such as alcoholism and vitamin B12 deficiency; as 
well as brain tumours and traumatic brain injury (Mirra and Hyman 2002). Some 5 
to 10% of multiple sclerosis (MS) patients also present with dementia (DeSousa et 
al. 2002; Benedict and Bobholz 2007). 
2.2 Genetics of dementia 
Alzheimer’s disease (AD) is the most common cause of dementia in Europe and North 
America (Mirra and Hyman 2002). It has both sporadic and familial forms. Familial 
AD is caused by autosomal dominant mutations in amyloid precursor protein (APP), 
presenilin 1 (PS1), or presenilin 2 (PS2). Mutations in each of these genes lead to 
increased amount of the amyloidogenic Aβ42 peptide. Although the familial cases of 
AD are rare, the genetic analysis of these cases has provided insight into the 
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pathogenic mechanisms of AD in general. According to the amyloid hypothesis, the 
Aβ peptide, which is produced by cleavage of the APP protein, aggregates in the brain 
to form amyloid plaques, which are considered as the triggering factor of AD 
development. PS1 and PS2 are involved in the cleavage of APP. A variant of 
apolipoprotein E (apoE) has been shown to be a risk factor for the sporadic form of 
AD. ApoE is inherited in three forms: ε2, ε3, and ε4. Individuals with one or two 
copies of the ε4 allele have increased risk of AD, whereas the ε2 allele is protective. In 
families with APP mutations, genetic variability in apoE modifies the age of onset of 
AD in such a way that the ε4 allele decreases the age of onset. ApoE encodes for an 
Aβ binding protein, linking the mechanisms of familial and sporadic forms. (Hardy 
and Gwinn-Hardy 1998; Mirra and Hyman 2002; Hardy 2006)  
Inspite of these advances, the exact mechanism of AD remains unresolved. Genetic 
bases of many other dementing neurodegenerative disorders have also been defined. 
Some examples are presented in Table 1.  
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TABLE 1. Examples of inherited dementias and their causative genes. (Mirra and 
Hyman 2002; Baker et al. 2006)  
Disease Gene Consequence 
CADASIL NOTCH3 unknown 
Frontotemporal dementia 
(FTD) 
Progranulin (PGRN) unknown 
 FTD with parkinsonism 
linked to chromosome 17 
(FTDP-17) 
Microtubule-associated 
protein tau (MAPT) 
Tau protein inclusions in 
neurons and/or glia 
Huntington’s disease Huntingtin (expanded 
CAG repeat) 
Nuclear inclusions of 
polyglutamine 
Prion disorders PRNP Aggregation of misfolded 
Prion protein (PrP) 
 
Although many genes in neurodegenerative diseases have been identified, there is 
still a long way to go to solve the exact pathogenic mechanisms of these disorders 
and develop therapies to treat or prevent them. 
2.3 Polycystic lipomembranous osteodysplasia with sclerosing 
leukoencephalopathy (PLOSL) 
Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 
(PLOSL; MIM221770), also known as Nasu-Hakola disease, is a progressive early 
onset dementia with bone fractures. First patients were described in the 1960’s in 
Finland and Japan (Terayama 1961; Järvi et al. 1964; Järvi et al. 1968; Hakola 1972; 
Nasu et al. 1973).  
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2.3.1 The clinical picture of PLOSL 
Early development of the PLOSL patients is normal. Symptoms usually begin with 
pain and fractures in wrists and ankles after minor injuries at early adulthood. 
Neurological symptoms appear as behavioral and personality changes at the fourth 
decade of life. In time, these develop into fullblown frontal lobe syndrome (loss of 
judgement, euphoria, lack of social inhibition, disturbance of concentration, lack of 
insight, lack of libido, and motor persistence). Patients develop progressing memory 
disturbance, which onsets at around the same time as the personality changes, but is 
initially less severe. Upper motor neuron involvement and gait disturbances are also 
observed. Most patients have epileptic seizures. The disease culminates in profound 
dementia and a vegetative state and leads to death before age 50 (Hakola et al. 1970; 
Paloneva et al. 2001; Klunemann et al. 2005).  
2.3.2 Histopathology of PLOSL 
PLOSL patients develop osteoporosis (loss of bone material). In radiography, cystic 
lesions in the bones of the extremities are observed (Paloneva et al. 2001). The 
cystic lesions of the bones are filled with convoluted lipid membranes, amorphous 
lipid material, and fat cells (Nasu et al. 1973). In neuroimaging, the patients show 
cerebral atrophy, calcification of the basal ganglia, and diffuse white matter changes 
(Paloneva et al. 2001; Klunemann et al. 2005). Neuropathological analysis 
demonstrates reduced brain weight, and frontally accentuated loss of the white 
matter. Histology shows an advanced loss of axons and myelin, activation of 
microglia and astrocytes, and vascular changes in PLOSL. The vascular changes 
consist of thickening of the vascular wall with narrowing of the lumen. No 
intraneuronal or glial pathologic inclusions have been observed in PLOSL, when 
stained for phosphorylated tau, α-synuclein, or ubiquitin. No Lewy bodies, plaques, 
congophilic angiopathy, phosphorylated neurofilament protein, or α-B-crystallin has 
been observed either (Paloneva et al. 2001).  
 19 
Two hypotheses on the pathogenic mechanism behind PLOSL have been proposed. 
The first hypothesis suggested that an error in systemic lipid metabolism would lead 
to breakdown of the myelin sheats and be responsible for PLOSL (Nasu et al. 1973; 
Wood 1978). The second hypothesis considered vascular damage as the primary 
defect that would lead to breakdown of the blood-brain barrier and chronic brain 
edema (Kalimo et al. 1994). Vascular alterations in the brain of PLOSL patients are 
observed, but it is not known whether they are primary or secondary (Paloneva et al. 
2001). Neither of these hypotheses has been proven right, so we turn to genetics to 
look for an answer. 
2.3.3 Genetics of PLOSL 
It was already noted on the first reports of the Finnish patients that PLOSL is an 
inherited disease (Hakola et al. 1970; Hakola 1972). PLOSL has an autosomal 
recessive pattern of inheritance. Although PLOSL is globally distributed, it is 
enriched in the Finnish population with an estimated population prevalence of 1-2 x 
10-6 (Hakola 1990). PLOSL is one of the diseases of the Finnish disease heritage. 
 
2.3.3.1 Finnish Disease Heritage 
The concept of Finnish disease heritage was established in 1973 (Norio et al. 1973). 
Rare inherited disorders that are overrepresented in Finland make up this entity. The 
group of disorders has grown from the twenty originally described to nerly fourty 
described to date. Most of the diseases have an autosomal recessive mode of 
inheritance. Two of the diseases are X-chromosomal and two autosomal dominant. 
The origin of enrichment of some rare diseases is in the population history of 
Finland. It has shaped the Finnish gene pool and resulted in the enrichment of some 
diseases in the Finnish population. At the same time, alleles for other diseases have 
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disappeared. The homogeneity of the Finnish gene pool has proven as a valuable 
tool in finding disease genes (Peltonen et al. 1999; Norio 2003). 
 
2.3.3.2 Identification of TYROBP as the first PLOSL gene 
PLOSL locus was assigned to chromosome 19q13.1 in Finnish patients by genome-
wide linkage, linkage disequlibrium, and haplotype analyses (Pekkarinen et al. 
1998a; Pekkarinen et al. 1998b). The PLOSL gene in this region was later identified 
as TYROBP (also known as DAP12 or KARAP) by sequencing the coding regions 
of the candidate genes in the region. All of the Finnish patients were shown to have 
a homozygous 5265 bp genetic deletion encompassing the exons 1-4 of the 5 exons 
of the TYROBP gene. No TYROBP mRNA or protein expression was detected in 
patient lymphoid cells by Northern and Western blots. A homozygous single base 
deletion in exon 3 of a Japanese patient was also identified (Paloneva et al. 2000). 
Additional mutations in TYROBP have been described since (TABLE 1, Fig. 1). 
Some non-Finnish PLOSL families were not linked to chromosome 19q13 
indicating genetic heterogeneity in PLOSL (Pekkarinen et al. 1998a). 
 
2.3.3.3 Identification of TREM2 as the second PLOSL gene 
Candidate gene approach was used to look for a second PLOSL gene in patients 
without mutations in TYROBP. The genes, the products of which were known to 
interact with the TYROBP protein, were considered as candidate genes. Analysis of 
segregation of the marker haplotypes flanking the candidate genes revealed co-
segregation of the 6p21.2 region with PLOSL. This region still contained three of 
the candidate genes: TREM1, TREM2, and NKP44. TREM2 was identified as the 
second PLOSL gene by sequence analysis of the genomic DNA in the non-Finnish 
PLOSL families (Paloneva et al. 2002). Several mutations in TREM2 have been 
described to date (TABLE 1, Fig. 1). Most of the mutations in TREM2 are point 
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mutations. Some of the mutations introduce premature stop codons while others 
change amino acids. 
With respect to neurologic and skeletal problems, mutations in TYROBP and 
TREM2 cause a similar clinical phenotype. However, the age of onset of bone pain, 
fractures, and dementia varies, even between patients with identical mutations 
(Klunemann et al. 2005). 
 
2.3.3.4 TYROBP and TREM2 in other neurodegenerative disorders 
Early onset dementia and involvement of frontal regions are also observed in 
neurodegenerative disorders other than PLOSL. Thus the question of TYROBP and 
TREM2 polymorphisms affecting other neurodegenerative disorders has been raised. 
TREM2 polymorphisms were analyzed in a study of Italian patients with 
Alzheimer’s disease and Frontotemporal Lobar Degeneration. None of the three 
single nucleotide polymorphisms (SNPs) analyzed were polymorphic and no new 
polymorphisms were found by sequencing the exons of TREM2 (Fenoglio et al. 
2007). Possible role of TYROBP and TREM2 polymorphisms in diseases other than 
PLOSL thus remains to be determined. 
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TABLE 1. PLOSL mutations. 
Mutation Country Reference 
TYROBP   
Del 5.3 kb (PLOSLFin) Finlad, Sweden, Norway (Paloneva et al. 2000; 
Tranebjaerg et al. 2000) 
Del 8 kb Brazil (Paloneva et al. 2002) 
2T>C / Met1Thr Japan (Kondo et al. 2002) 
141delG / FS and 
termination at aa 52 
Japan (Paloneva et al. 2000; 
Kondo et al. 2002) 
145G>C / Gly49Arg Portugal (Baeta et al. 2002) 
154-155ins42nt United Kingdom 
(Scotland), Germany 
(Klunemann et al. 2005) 
and not reported 
262G>T / Glu87Stp Japan (Kuroda et al. 2007) 
TREM2   
40G>T / Glu14Stp Germany (Paloneva et al. 2003) 
97C>T / Gln33Stp Belgium, Italy (Soragna et al. 2003; 
Klunemann et al. 2005) 
132G>A / Trp44Stp Bolivia (Paloneva et al. 2002) 
233G>A / Trp78Stp Sweden (Paloneva et al. 2002) 
267delG / FS France (Turkey) (Klunemann et al. 2005) 
313delG / FS Germany (Klunemann et al. 2005) 
377T>G / Val126Gly Canada, UK (Sri Lanka) (Klunemann et al. 2005) 
401A>G / Asp134Gly USA (Slovakia) (Paloneva et al. 2002) 
482+2T>C / SP Italy (Paloneva et al. 2002) 
558G>T / Lys186Asn Norway (Paloneva et al. 2002) 
TP, truncated protein; FS, frameshift; SP, splicing mutation. 
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Figure 1. DAP12 and TREM2 genes and PLOSL mutations. 
2.4 DAP12 protein 
The first PLOSL gene, TYROBP, encodes a 12 kDa DAP12 protein in humans. 
DAP12 is a type I transmembrane protein of 113 amino acids (Lanier et al. 1998). It 
contains a 27 amino acid leader segment, a 14 amino acid extracellular domain, a 24 
amino acid transmembrane domain, and a 48 amino acid intracellular domain. 
DAP12 is a signalling adapter protein. In its intracellular domain, DAP12 contains 
an intracellular tyrosine based activation motif (ITAM, D/ExxYxxL/I-x6-8-YxxL/I 
(Reth 1989)) with the sequence ESPYQELQGQRSDVYSDL and potential 
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phosphorylation sites for protein kinase C and casein kinase II (Fig. 2). In its 
transmembrane region, DAP12 contains a conserved aspartic acid (D) residue, 
important for its association with receptor molecules (Lanier et al. 1998). 
 Killer cell activating receptor-associated protein (KARAP) was identified as a 
disulfide-linked tyrosine-phosphorylated dimer that selectively associates with the 
activating natural killer receptors (NKRs) (Tomasello et al. 1998). Karap gene is 
localized on mouse chromosome 7, spans 3.56 kb, contains five exons, and produces 
an open reading frame of 342 bp. The predicted protein contains a 27 amino acid 
leader peptide, a 16 amino acid extracellular domain, a 24 amino acid 
transmembrane domain, and a 47 amino acid intracellular domain with an ITAM 
(Y65QELQGQRPEVY76SDLN). Karap also contains cysteines in the extracellular 
region and a charged amino acid (D25) in its transmembrane domain. Karap is a 9.6 
kDa type I transmembrane protein. The Karap polypeptide was found to have 73% 
amino acid identity with and to be orthologous to the human DAP12 (Tomasello et 
al. 1998). 
 
Figure 2. Schematic representation of the DAP12 protein dimer. The negatively 
charged aspartic acid (D) residue is needed for the association of Dap12 
with receptor molecules. Intracellular tyrosine based activation motif 
(ITAM) is needed for signal transduction. 
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2.4.1 DAP12 mediated signal transduction 
Natural killer (NK) cells are lymphocytes of the innate immune system.  They are 
involved in the early defense against foreign cells as well as cells undergoing stress 
such as viral and bacterial infection, parasites, or malignant transformation. NK cells 
exert direct cytotoxicity and produce cytokines and chemokines. The activation 
status of NK cells is controlled by a dynamic equilibrium between excitatory and 
inhibitory signals (Vivier et al. 2004). DAP12 is expressed as a disulphide-bonded 
homodimer in NK cells (Lanier et al. 1998). It associates non-covalently with killer-
cell inhibitory receptor (KIR) family members that do not contain intracellular 
tyrosine based inhibitory motifs (ITIMs) in their cytoplasmic domains. Crosslinking 
of KIR-DAP12 complexes leads to phosphorylation of the DAP12 ITAM and 
cellular activation, as demonstrated by tyrosine phosphorylation of cellular proteins 
and upregulation of early-activation antigens (Fig. 3). The mechanism of activation 
might be explained by the binding of ZAP-70 and Syk protein tyrosine kinases to 
phosphorylated DAP12 intracellular peptides (Lanier et al. 1998).  
In murine NK cells, Dap12 associates with activating Ly49D and H isoforms 
(McVicar et al. 1998). Ly49 receptors are a family of mouse NK cell receptors with 
both inhibitory and activating members. Ligation of the Ly49D-Dap12 complex 
results in tyrosine phosphorylation of phosphoplipase Cγ1, Cbl, and p44/p42 
mitogen-activated protein kinase, as well as calcium mobilization. It also leads to 
activation of Syk but not Zap-70 (McVicar et al. 1998). Syk plays a critical role in 
the NK cell lytic pathway whereas Zap-70 is dispensable (Brumbaugh et al. 1997). 
Inspite of the involvement of DAP12 in NK cell activation, DAP12 deficient human 
NK cells are able to kill K562 erythroleukaemia cells as efficiently as control NK 
cells (Paloneva et al. 2000). 
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Figure 3. Dap12 mediated signal transduction. Modified from (Turnbull and Colonna 
2007) 
In addition to NK cells, DAP12 is expressed in multiple other hematopoietic cell 
types. In neutrophils and macrophages, DAP12 has been shown to be involved in 
integrin signalling (Mocsai et al. 2006). Integrin signalling leads to phosphorylation 
of the tyrosine residues of the DAP12 ITAM by Src kinases and activation of Syk. 
DAP12 does not associate directly with the integrins, but the association is most 
likely mediated by one or some of the DAP12 associated receptors (Mocsai et al. 
2006). To date, DAP12 has been shown to associate with several receptors in human 
and mouse (TABLE 2.). 
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TABLE 2. Dap12 associated receptors. Modified from (Takaki et al. 2006). 
Common name Expression Structure 
Human and mouse   
CD94/NKG2C NK, T-cell subset C-type lectin, 
heterodimer 
PILRβ NK, granylocyte, 
macrophage, DC 
Ig-domain (1) 
SIRPβ1 Granulocyte, monocyte, 
macrophage, DC 
Ig-domain (3) 
MDL-1 Monocyte, macrophage C-type lectin, homodimer 
TREM-1 Monocyte, macrophage, 
granulocyte, neutrophil 
Ig-domain (1) 
TREM-2 Macrophage, DC, osteoclast, 
microglia 
Ig-domain (1) 
Human   
NKp44 Activated NK, IPC subset, 
rare γδ-T-cell 
Ig-domain (1) 
KIR3DS1 NK, T-cell subset Ig-domain (3) 
KIR2DS1, 2DS2, 2DS4 NK, T-cell subset Ig-domain (2) 
IREM-2/CLM2 Monocyte, DC precursor Ig-domain (1) 
Mouse   
Ly49D, H, L, M, P, R, 
U, W 
NK C-type lectin, homodimer 
NKG2D-S NK, T-cell subset C-type lectin, homodimer 
Siglec-H IFN-producing cells (IPC) Ig-domain (2) 
MAIR-II Mast cell, granulocyte, 
macrophage, DC 
Ig-domain (1) 
CD200R3 Mast cell, basophil Ig-domain (2) 
CD200R4 NK, monocyte, macrophage Ig-domain (2) 
TREM-3 Macrophage  Ig-domain (1) 
Number of Ig-domains of the receptor is in brackets. 
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2.5 TREM2 protein 
Triggering receptor expressed on myeloid cells-2 (TREM2), encoded by the second 
PLOSL gene, is a transmembrane receptor of the Ig-superfamily. The TREM family 
of cell surface receptors participate in a variety of cellular functions in myeloid cells. 
TREM family members associate with DAP12 for signal transduction. TREM1, the 
member of the TREM family that was identified first, activates neutrophils and 
monocytes (Bouchon et al. 2000; Bouchon et al. 2001a). TREM2 was identified in 
human in vitro induced dendritic cells (Bouchon et al. 2000). It is a ∼40 kDa 
glycoprotein. Its size is reduced to 26 kDa after N-deglycosylation. TREM2 has a 
single variable (V)-type extracellular domain, a charged lysine residue (K) in its 
transmembrane domain, and a short cytoplasmic tail with no known signalling 
motifs (Fig. 4). The charged lysine in the transmembrane domain of TREM2 is 
needed for its association with DAP12 (Bouchon et al. 2000; Bouchon et al. 2001b).  
Mouse Trem2 was identified in macrophages as a transmembrane receptor with a 
single Ig (V) domain, a positively charged lysine in its transmembrane domain, and 
a short cytoplasmic tail (Daws et al. 2001). Mouse Trem2 associates with Dap12 and 
its crosslinking leads to nitric oxide (NO) release by macrophages. The mouse 
Trem2 gene is located on mouse chromosome 17.  
A splice variant of Trem2, which lacks the transmembrane domain and probably 
encodes a soluble form of the protein, was described in mouse microglia (Schmid et 
al. 2002). This svTrem2 differs from Trem2 by having a 55 bp insertion between 
exons 3 and 4. Sequence analysis indicates that splicing of exon 3 to an alternative 
splice site located 55 nucleotides upstream of exon 4 forms this variant. The 
insertion causes a frameshift generating a putative svTrem2 protein that lacks the 
transmembrane domain and is 22 amino acids longer than Trem2 (Schmid et al. 
2002). In our RT-PCR experiments we have observed a similar transcript in the 
C57BL/6 mouse CNS (A. Kiialainen, unpublished observation). No further reports 
on the properties or function of the svTrem2 have been published. 
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Figure 4. The DAP12/TREM2 receptor complex. 
2.6 Expression and function of the DAP12/TREM2 complex 
DAP12 was originally cloned from a dendritic cell (DC) library (Lanier et al. 1998). 
Expression of DAP12 transcripts was detected in human peripheral blood 
leukocytes, spleen, and NK cell lines.  DAP12 expression was also detected in 
cDNA libraries from peripheral blood mononuclear cells, DCs, peripheral blood 
monocytes and NK cells (Lanier et al. 1998). Karap expression was detected in NK 
cells, T cells, B cells, mast cells, endothelial and epithelial cells as well as neural 
cell lines (Tomasello et al. 1998). TREM2 was also first identified in DCs (Bouchon 
et al. 2000). Whereas DAP12 is expressed on several hematopoietic cell types, 
TREM2 expression seems to be restricted to myeloid cells. When DAP12 was 
identified as the first PLOSL gene, it was already suggested that myeloid origin of 
microglia in the brain and osteoclasts in the bone could explain the tissue specificity 
of the PLOSL phenotype (Paloneva et al. 2000). 
 30 
2.6.1 Myeloid cells 
Myeloid cells are derived from hematopoietic precursors of the bone marrow (Fig. 
5). Hematopoietic stem cells first differentiate into myeloid progenitors, which then 
give rice to monocytes, osteoclast precursors, and microglia. Monocytes further 
differentiate into macrophages and myeloid dendritic cells. Pre-osteoclasts fuse into 
mature osteoclasts (Colonna 2003).  
 
 
 
Figure 5. Myeloid cells expressing DAP12 and TREM2.  Modified from (Colonna 
2003) 
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2.6.2 Dap12 and Trem2 in dendritic cells and macrophages 
TREM2 associates with DAP12 in human monocyte-derived DCs (Bouchon et al. 
2001b). TREM2 is not expressed on monocytes and is completely downregulated on 
DCs when DC maturation is induced by lipopolysaccharide (LPS), tumor necrosis 
factor (TNF)-α, CD40L-expressing cells, interleukin (IL)-1β, CpG oligonucleotodes, 
or aggregated immunoglobulin (Ig) G. Ligation of TREM2 with a monoclonal 
antibody (mAb) resulted in rapid rise in intracellular calcium levels of DCs indicating 
activation. Crosslinking of TREM2 also led to tyrosine phosphorylation of 
extracellular signal-regulated kinase (ERK1/2) and prolonged survival of DCs. This 
effect was blocked by ERK inhibitor, indicating that TREM2 induces survival of DCs 
through activation of the ERK pathway. In DCs, the DAP12/TREM2 complex 
promoted upregulation of CC chemokine receptor 7. Ligation of TREM2 also induced 
increased expression of MHC class II, CD40, and CD86 (B7.2), which are all involved 
in T cell stimulation. TREM2 induced activation was dependent on protein tyrosine 
kinase (PTK), partially dependent on ERK and independent of nuclear factor κ-B (NF-
κB) and stress-activated protein kinase (p38/SAPK). Thus TREM2 seems to be an 
activating receptor on DCs and was suggested to be important in normal homeostasis 
of DCs (Bouchon et al. 2001b). 
When mouse Trem2 was described, its expression was detected in macrophage cell 
lines (Daws et al. 2001). Dap12 and Trem2 protein expression has been detected in 
mouse bone marrow derived macrophages (Hamerman et al. 2006). In vivo, Trem2 
was induced on tissue resident macrophages in the presence of type-II inflammation 
and on macrophages newly differentiated from monocytes leaving the circulation 
(Turnbull et al. 2006). It has been recently proposed that the Dap12/Trem2 complex 
has an inhibitory rather than activating role in macrophages (Hamerman et al. 2006; 
Turnbull et al. 2006). It was first noted that Dap12 deficient macrophages produce 
more inflammatory cytokines in response to Toll-like receptor (TLR) stimuli than 
wild type macrophages. It was thus suggested that Dap12 mediated signals 
 32 
negatively regulate TLR signalling (Hamerman et al. 2005). Similar to Dap12 
knockout macrophages, Trem2 knockdown in mouse macrophages increased TLR 
induced TNF production. A chimeric protein composed of the extracellular domain 
of Trem2 and the intracellular domain of Dap12 inhibited TLR and Fc receptor 
(FcR) induced TNF production in Dap12 deficient macrophages and rescued it to the 
wild type level. It was thus concluded that Trem2 is the Dap12 associated receptor 
involved in inhibitory signalling (Hamerman et al. 2006). Using Trem2 knockout 
macrophages it was also found that Trem2 inhibits cytokine production in response 
to TLR ligands (Turnbull et al. 2006). These studies show that the Dap12/Trem2 
complex inhibits macrophage activation (Fig. 6). 
 
 
Figure 6. Inhibitory signalling through the DAP12/TREM2 complex.  Modified from 
(Turnbull and Colonna 2007) 
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2.6.3 Function of the DAP12/TREM2 complex in osteoclasts 
Osteoclasts are multinucleated giant cells involved in bone resorption and 
homeostasis (Teitelbaum 2000; Väänänen et al. 2000). Studies by others and us have 
shown that DAP12 and TREM2 deficient peripheral blood mononuclear cells 
(PBMC) isolated from PLOSL patients fail to differentiate into multinucleated 
osteoclats in vitro (Cella et al. 2003; Paloneva et al. 2003). DAP12 and TREM2 
deficient osteoclast-like cells show reduced bone resorption activity and impaired 
actin reorganization. Dap12 deficient mouse cells are also incapable of forming 
multinucleated osteoclasts in vitro. Osteoclast formation is restored when the cells 
are retrovirally reconstituted with Dap12 (Humphrey et al. 2004). Dap12 or Trem2 
stimulation on RAW264.7 cells (a tumor cell line capable of forming osteoclasts) 
leads to increased formation of osteoclast-like multinucleated cells (Humphrey et al. 
2004). Trem2 regulates multinucleation as well as resorption and migration of 
mature osteoclasts in vitro (Humphrey et al. 2006). Thus, the Dap12/Trem2 complex 
plays an important role in osteoclast differentiation. This is interesting considering 
the bone phenotype in PLOSL, but the mechanism of development of the bone 
abnormalities still requires further study. 
2.6.4 Dap12 and Trem2 expression in microglia 
Microglia are the resident immune cells of the CNS (Aloisi 2001). Microglia were 
shown to express Trem2 transcripts (Schmid et al. 2002). Others and we have 
detected Dap12 and Trem2 protein expression in microglia (Kaifu et al. 2003; 
Roumier et al. 2004; Takahashi et al. 2005)(I). Role of the DAP12/TREM2 complex 
in microglia and its consequences to PLOSL pathogenesis will be further considered 
in the Discussion.  
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2.7 Trem2 ligand 
Since it is clear that the Dap12/Trem2 signalling is disturbed in PLOSL, it would be 
of interest to know what triggers this signalling pathway. The ligand for Trem2 is 
currently unknown. It has been suggested that Trem2 can bind both self- and 
pathogen-expressed ligands. It was shown that a Trem2-IgG1Fc fusion protein binds 
specifically to gram-negative and gram-positive bacteria and yeast. Fluorescently 
labelled Escherichia coli and Staphylococcus aureus bound to Trem2 transfected 
cells. Bacterial products such as LPS and peptidoglycan inhibited fusion protein 
binding. The fusion protein also bound to a number of astrocytoma cell lines. It was 
suggested that the ligand recognition is partly based on charge (Daws et al. 2003). It 
was recently suggested that macrophages express Trem2 ligand, since they bind a 
Trem2-Fc fusion protein, and that Trem2 binding to its ligand in the same cell would 
lead to internalization of the complex (Hamerman et al. 2006). It was also proposed, 
but not shown, that the same would apply to microglia. 
2.8 Mouse as a model in biomedical research 
In order to study disease mechanisms, animal models are needed in addition to cells 
and in vitro experiments to analyze what happens in whole organisms. Although a 
lot has been learned by studying lower organisms such as bacteria, yeast, worms, 
and flies, mammalian models are also needed to understand disease processes in 
human. Mouse is widely used as a mammalian model animal, because of its small 
size, short lifespan, and short generation time.  Most of the human genes have a 
mouse homolog, which can be manipulated to produce a mouse model of a human 
disease. Genetic manipulation of mouse is made possible by developments in 
different transgenic technologies for targeted gene manipulation and the availability 
of embryonic stem (ES) cell lines (Glaser et al. 2005). Availability of inbred mouse 
lines, phenotypic databases, and the mouse genome sequence are important tools for 
current biomedical research (Waterston et al. 2002; Guenet 2005). 
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2.9 DAP12 deficient mice 
Three different Dap12 deficient mice have been described to date (Bakker et al. 
2000; Tomasello et al. 2000; Kaifu et al. 2003). Immunological as well as central 
nervous system and bone phenotypes have been described in the mice. 
2.9.1 Immunological phenotypes in Dap12 deficient mice 
Bakker et al. generated Dap12 knockout mice using the cre-lox strategy to delete 
exons 3 and 4 of the Tyrobp gene on mouse chromosome 7 (Fig. 7A) (Bakker et al. 
2000). 129/SV ES cells were introduced into the C57BL background. The mice had 
normal viability, weight, fertility, growth, and gross anatomy. Since Dap12 is 
implicated in NK and myeloid cell function, the immune cells of the mice were 
analyzed in detail. The mice had normally developed hematological compartment, 
except for increased number of major histocompatibility (MHC) class II positive 
DCs in the dermis compared to heterozygous controls. The activating Ly49D NK 
cell receptors that associate with Dap12 were inactive in these mice, but the NK 
cells of the mice were still able to lyse tumor cell lines. Thus Dap12 was found non-
essential for cytotoxicity against tumor cells in mice. Dap12 knockout peritoneal 
macrophages as well as dendritic cells isolated from spleen or derived from bone 
marrow were identical to those derived from heterozygous controls. (Bakker et al. 
2000) 
Interestingly, Dap12 knockout mice were found to be resistant to experimental 
autoimmune encephalomyelitis (EAE) induced with myelin oligodendrocyte 
glycoprotein (MOG) peptide. EAE resembles some of the characteristics of the 
human disease multiple sclerosis (MS) and is studied as a mouse model of 
autoimmune demyelination. Because the CD4+ T cells of the Dap12 knockout mice 
did not produce interferon-γ (IFNγ) when restimulated with the MOG peptide, it was 
suggested that the resistance to EAE was due to inadequate T cell priming in Dap12 
knockout animals. (Bakker et al. 2000) 
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Figure 7. Constructs used to generate Dap12 deficient mice by A) Bakker et al. (2000), 
B) Tomasello et al. (2000), and C) Kaifu et al. (2003) 
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Tomasello et al. generated Dap12 knockin mice with a non-functional ITAM 
(KΔY75/KΔY75, Fig. 7B) (Tomasello et al. 2000). The KΔY75/KΔY75 mice lack the 
Y75 residue of the ITAM and the following C-terminal amino acids, which are 
replaced by other amino acids that do not correspond to any known protein. The 
mutation was introduced into the exon 5 of the Tyrobp gene using the cre-lox strategy. 
129 Ola ES cells were introduced into Balb/c background, which was then crossed 
with C57BL/6. The KΔY75/KΔY75 mice developed normally and were fertile. The 
knockin mice showed similar numbers of lymphoid and myeloid cell subsets as 
heterozygous and wild type controls. NK cells of these mice expressed the activating 
Ly49D and Ly49H receptors on the cell surface, but the receptors were non-functional. 
The natural cytotoxicity of NK cells from KΔY75/KΔY75 mice towards macrophage 
cell lines, but no other targets, was impaired. (Tomasello et al. 2000) 
The distribution of DCs in KΔY75/KΔY75 mice was also studied. An accumulation 
of myeloid DCs in mucosal tissues was observed, but no detectable changes in 
phenotype or distribution of DCs in secondary lymphoid organs was seen. DCs were 
also cultured from bone marrow progenitors with granulocyte monocyte colony 
stimulating factor (GM-CSF). The in vitro derived DCs exhibited normal maturation 
process and LPS response as well as allostimulatory property for naïve CD4+ T 
cells. The migratory capacity of skin DCs of the Dap12 knockin mice was 
comparable to normal, but hapten induced contact sensitivity was impaired 
indicating a defect in priming of hapten-specific CD8+ T cells, which are responsible 
for the contact sensitivity, by skin DCs. (Tomasello et al. 2000) 
These studies showed that Dap12 is essential for normal DC function in mice and 
especially for the ability of DCs to prime T cells. 
2.9.2 Neurological defects in Dap12 deficient mice 
Kaifu et al. generated Dap12 knockout mice by replacing the putative promoter and 
exons one to three of the Tyrobp gene with the neo cassette (Fig. 7C) (Kaifu et al. 
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2003). Mice were generated into the 129/SVJ and C57BL/6 hybrid background. 
Knockout cells did not express any Dap12 protein. Mice grew normally, were fertile 
and did not show any gross behavioural abnormalities up to 24 months. Since Dap12 
mutations had been shown to cause PLOSL in humans at this point, the effect of the 
knockout on the CNS of the mice was analyzed in detail. No differences were 
observed in microglial (F4/80), neuronal (Nissl), neurofilaments (NF), or astroglial 
(GFAP) immunohistochemical stainings between Dap12 knockout and wild type 
control mice. Further, no difference in the number of apoptotic neurons 
(Nissl+TUNEL staining) and no evidence for cerebral inflammation (HE staining) 
was observed.  A reduced myelin basic protein (MBP) staining was observed in the 
thalamus of Dap12 knockout mice. Electron microscopy of the thalami showed 
reduction in the number of myelinated axons, intact endothelial cells and basement 
membranes, degenerated synapses and accumulated synaptic vesicles. No 
differences were seen in analysis of motor function, nociceptive responses, and 
learning of the Dap12 knockout mice. A reduced startle reflex to acoustic stimuli as 
well as significantly reduced prepulse inhibition were observed in the Dap12 
knockout mice suggesting impairment of sensorimotor gating. Both processes 
involve thalamus and γ-aminobutyric acid (GABA) mediated inhibition. Also, 
impairment in developmental changes of the decay time constant in GABAergic 
miniature inhibitory postsynaptic currents (mIPSCs) of Dap12 knockout mice was 
observed. (Kaifu et al. 2003) 
Roumier et al. (Roumier et al. 2004) analyzed synaptic function in the Dap12 
deficient KΔY75 mice (Tomasello et al. 2000). Long-term potentiation (LTP) in 
these mice was enhanced and partly independent of the NMDA receptor (NMDAR). 
LTP induction requires postsynaptic Ca2+ influx, usually through NMDARs 
(Malenka and Nicoll 1993). It was concluded that by affecting LTP Dap12 
deficiency impacts on hippocampal synaptic plasticity. The mice also showed 
changes in synaptic glutamate receptor content by electrophysiology and 
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biochemical analysis. The AMPA receptor GluR2 subunit expression was decreased 
in the postsynaptic densities, but not in the whole membrane fraction, demonstrating 
specific impairment of receptor accumulation into synapses. A dramatic decrease in 
the brain derived neurotrophic factor (BDNF) tyrosine kinase receptor B (TrkB) 
expression was also observed in the Dap12 mutant synapses. BDNF signalling 
affects NMDAR function and thus also LTP. Dap12 expression was detected only in 
microglia, but not in astrocytes or oligodendrocytes both in primary mixed glial 
cultures and in vivo. It was thus suggested that microglial Dap12 affects synaptic 
function and plasticity through a novel microglia-neuron interaction. It is also noted, 
but not shown, that these mice show thalamic hypomyelinosis in old animals similar 
to that described in Dap12 knockout mice by Kaifu et al (Kaifu et al. 2003). 
(Roumier et al. 2004) 
Nataf et al. (Nataf et al. 2005) analyzed the brain pathology in the KΔ75 Dap12 
deficient mice (Tomasello et al. 2000). Histological analysis of CNS of adult Dap12 
deficient mice showed diffuse hypomyelination predominating in anterior brain 
regions not accompanied with oligodendrocyte degeneration or microglial 
activation. It was thus suggested that the hypomyelination was due to developmental 
defect of myelin formation. A dramatic reduction in microglial cell number in 
postnatal mutant mice as well as impairment of microglial cell differentiation in 
vitro was also observed. Microglia were differentiated from bone marrow precursors 
amplified with FLT3-ligand with glial cell conditioned medium (described in 
(Servet-Delprat et al. 2002)). (Nataf et al. 2005) 
In light of these studies it seems that Dap12 deficiency affects myelin stability and 
synaptic function in the CNS, which are both interesting in light of the CNS 
symptoms in PLOSL (see Discussion). 
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2.9.3 Bone abnormalities in Dap12 deficient mice 
In addition to CNS changes, Dap12 deficient mice show bone abnormalities. They 
develop increased bone mass (osteopetrosis) (Kaifu et al. 2003). Micro-CT 3D 
imaging showed an increase in trabecular bone mass of the tibia of 40-week-old 
mice and hematoxylin and eosin staining showed higher amounts of bone trabecula 
in femurs of six weeks old Dap12 deficient mice than littermates. Number and 
morphology of osteoclasts in tissue sections of femurs of six weeks old mice was 
similar in Dap12 deficient mice and control littermates. The in vitro differentiation 
of Dap12 knockout bone marrow cells into multinucleated osteoclasts in the 
presence of macrophage colony stimulating factor (M-CSF) and receptor activator of 
nuclear factor kappa B ligand (RANKL) or TNF-α was severely impaired. The 
osteoclasts formed by the Dap12 knockout cells did not have an actin ring 
characteristic of mature and functional osteoclasts and their ability to form 
resorptive pits on dentin slices was significantly reduced (Kaifu et al. 2003). A block 
of in vitro osteoclast differentiation and altered bone remodelling were also 
observed in the KΔY75 mice (Roumier et al. 2004; Nataf et al. 2005). Increased 
bone mass was also reported in the Dap12 knockout mice described by Bakker et al.  
Cells from these mice were incapable of forming multinucleated osteoclasts in vitro. 
Osteoclast formation was restored when the cells were retrovirally reconstituted with 
Dap12 (Humphrey et al. 2004).  
In both, human and mice, functional Dap12 is required for the formation of 
multinucleated and functional osteoclasts in vitro (Cella et al. 2003; Kaifu et al. 
2003; Paloneva et al. 2003; Humphrey et al. 2004). Opposing in vivo phenotypes are 
observed in mouse and human, since Dap12 deficient mice develop osteopetrosis 
(increase in bone mass) and PLOSL patients suffer from osteoporosis (bone loss). 
Reasons for this remain to be solved. 
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2.10 TREM2 knockout mice 
Trem2 knockout mice have been recently described (Turnbull et al. 2006). The mice 
were generated into mixed 129 and C57BL/6 background. Exons 3 and 4 of the 
Trem2 gene were deleted using the cre-lox strategy (Fig. 8). This resulted in deletion 
of a part of the transmembrane and cytoplasmic domains of the protein. Mice were 
backcrossed to the C57BL/6 background. The mice did not show any gross 
abnormalities. Wild type mouse bone marrow derived macrophages (BMDM) 
expressed Trem2. BMDM of the knockout mice did not express any Trem2 protein. 
Trem2 knockout BMDM produced increased amounts of TNF-α and IL-6 in 
response to the Toll-like receptor (TLR) agonists LPS, zymosan, and CpG. 
Peritoneal macrophages isolated from Trem2 knockout mice also produced 
increased amounts of TNF-α and IL-6 in response to LPS but not zymosan. The 
increase in cytokine production was smaller in the peritoneal macrophages than in 
the in vitro derived BMDM. It was concluded that Trem2 functions to attenuate 
macrophage response to microbial products. (Turnbull et al. 2006)  
Preliminary data from the Trem2 knockout mice suggests that they have accelerated 
osteoclastogenesis. More rapid fusion of the Trem2 knockout cells into osteoclasts 
capable of bone resorption was noted in vitro. The Trem2 knockout mice did not 
show osteopetrosis similar to that observed in Dap12 deficient mice (Klesney-Tait et 
al. 2006). It should be noted that, these data are presented as unpublished 
observations in a review and the original data has not been published. No reports on 
the CNS phenotype of the Trem2 knockout mice have been published to date. 
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Figure 8. Construct used to generate Trem2 knockout mice. Modified from (Turnbull 
et al. 2006) 
2.11 Genome wide expression analysis 
Completion of the human and mouse genome projects (Lander et al. 2001; 
Waterston et al. 2002), and development of the microarray hybridization 
technologies (Schena et al. 1995; Lockhart et al. 1996) has made it possible to 
analyze the expression of all of the genes of these organisms in one experiment. 
Instead of introducing bias by choosing candidate genes to study their expression 
between different conditions, we can now study the expression of all of the genes in 
the genome at once. This approach allows us to identify changes of expression in 
complete metabolic pathways in addition to individual genes, which makes it a 
valuable tool for studying disease mechanisms. The genome wide expression 
analysis has proven successful especially in cancer studies, where cancer subtypes 
with different drug response properties have been identified (Cheok and Evans 
2006) and gene expression profiles have helped to predict disease outcome 
(Pomeroy et al. 2002). 
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3 AIMS OF THE STUDY 
The general aim of this study was to gain insight into the pathogenic mechanisms of 
PLOSL. The more specific aims were: 
 
First: to identify the spatial and temporal expression patterns of DAP12 and TREM2 
in the CNS and to identify the CNS cell types, which express both of these gene 
products.  
 
Second: to determine which pathways and cellular processes are affected by the lack 
of DAP12 and TREM2 in human cells that normally express these gene products.  
 
Third: to determine which pathways and cellular processes are affected by the lack 
of DAP12 in the CNS and microglia of knockout mice. 
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4 MATERIALS AND METHODS 
4.1 Methods 
Methods used in this thesis are described in the original publications included. 
 
TABLE 3. Methods. 
Method Original publication 
Antibody production I 
Confocal and light microscopy I, II, III 
Dendritic cell culture II 
Enzyme-linked immunosorbent assay (ELISA) II 
Flow cytometry II 
Glial and neuronal primary cell culture I, III 
Immunofluorescence I, II, III 
Immunohistochemistry III 
In situ hybridization I 
Macrophage culture II 
Microarray analysis II, III 
Migration assay III 
Northern blot I, II 
PCR II 
Proliferation assay III 
Quantitative real time PCR I, II 
Reverse transcriptase-PCR (RT-PCR) I 
Sequencing II 
Western blot III 
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4.2 Ethical aspects 
Studies on PLOSL patient cells were approved by the Ethical Committee of the 
Hospital District of Helsinki and Uusimaa, Helsinki, Finland (II). Informed consent 
was obtained from all subjects. Animal studies were approved by the Chancellor’s 
Animal Research Committee at the University of California Los Angeles (I), and the 
Ethical Committee for the use of Laboratory Animals at the National Public Health 
Institute, Helsinki, Finland (I, III). 
4.3 Software and databases 
Commercially and freely available software as well as software developed in our 
laboratory was used in this thesis. Expression data was submitted to the Gene 
expression omnibus (GEO) database and made freely available at publication (II). 
 
TABLE 4. Software and databases. 
Software/Database Reference Original publication 
Cytoscape www.cytoscape.org III 
Gene Expression Omnibus 
(GEO) 
www.ncbi.nlm.nih.gov/geo II 
Genespring Commercial (Agilent) II, III 
Gene Ontology Tree 
Machine (GOTM) 
http://genereg.ornl.gov/gotm II 
GO2Cytoscape Developed by Juha 
Saharinen at NPHI 
III 
Iterative Pathway Analysis Developed by J.S. at NPHI II, III 
R www.r-project.org III 
Statistical Package for 
Social Sciences (SPSS) 
Commercial II 
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5 RESULTS 
5.1 Dap12 and Trem2 expression in the mouse central nervous 
system (CNS) 
In the first part of the study we identified the cell types important for the CNS 
pathogenesis of PLOSL (I). 
5.1.1 Dap12 and Trem2 are expressed in mouse brain from embryonic 
stage to adulthood 
We first studied the expression of Dap12 and Trem2 in the developing mouse CNS 
by Northern blot and quantitative real-time PCR. Northern blot analysis of mouse 
brain at embryonic day 18, postnatal day one, day three, one week, two weeks, three 
weeks, one month, two months, three months, six months, and twelve months 
showed expression of both Dap12 and Trem2 mRNAs (Fig.1 in I). In order to 
quantitate the expression of Dap12 and Trem2 during mouse brain development, 
total RNA from the brain of C57/BL6 mice at embryonic day 17, one week, two 
weeks, one month, six months, and twelve months was analyzed with real-time 
quantitative PCR. Both Dap12 and Trem2 mRNAs were detected at all time points 
tested. Dap12 and Trem2 expression levels showed slight variation during 
development, but the changes in the steady state level were not significant at any 
time point up to twelve months. Thus, neither Dap12 nor Trem2 expression seem to 
be developmentally regulated, at least at the transcript level. Dap12 expression was 
higher than Trem2 at all developmental stages. 
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5.1.2 Dap12 and Trem2 transcripts show a glial expression pattern 
We characterized the spatial expression pattern of Dap12 and Trem2 by in situ 
hybridization. Brain sections of neonatal (P1), two week, three month, and six 
month old mice were hybridized with Dap12 and Trem2 specific radioactively 
labeled probes. In the P1 brain sections, Dap12 and Trem2 transcripts showed a 
spatial co-localization in several brain regions, including the cerebral cortex (Ctx), 
the hippocampus (Hc) and the thalamus (Th) (Fig. 9). Dap12 and Trem2 expression 
patterns were very similar throughout the development. At P1, both Dap12 and 
Trem2 were mostly expressed in sub-cortical regions, especially in the thalamus. In 
the cortex, the expression was observed close to the white matter. The expression 
patterns imply glial expression of Dap12 and Trem2. In older mice expression of 
both transcripts was scattered throughout the CNS.  
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Figure 9.  Dap12 and Trem2 expression in the developing mouse CNS. Dap12 and 
Trem2 are mostly expressed in the sub-cortical regions at postnatal day 1 
(P1). At two weeks, the expression of both transcripts is scattered throughout 
the CNS. Ctx=cortex, CPu=caudate putamen, Hc=hippocampus, 
Th=thalamus, and V=ventricle. 
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5.1.3 Microglial cells and oligodendrocytes express Dap12 and Trem2 
In addition to neurons, CNS contains three types of glial cells: astrocytes, 
oligodendrocytes, and microglia. To characterize the specific cell type(s) expressing 
Dap12 and Trem2, we performed reverse transcriptase PCR (RT-PCR) and real-time 
quantitative PCR analyses. Total RNA from the cerebral cortex, and CNS-derived 
primary neuronal and glial cell cultures of C57BL/6 mice were analysed by RT-
PCR. Dap12 and Trem2 transcripts were detected in the cortex and in the mixed 
glial cell cultures (Fig. 10B). No Dap12 expression and little Trem2 expression were 
detected in neuronal cultures. RNA from rat primary cultures of astrocytes, 
oligodendrocytes and microglia were further analysed by real time quantitative PCR. 
Dap12 and Trem2 transcripts were detected in microglial cells and 
oligodendrocytes, but not in astrocytes (Fig. 10C). The relative expression levels of 
both Dap12 and Trem2 were considerably higher in microglial cells than in 
oligodendrocytes. 
To monitor Dap12 and Trem2 expression at the protein level, primary glial cell 
cultures from C57BL6 mice were prepared and immunostained for Dap12 and 
Trem2. The cells were first characterized by immunostaining with cell type specific 
marker-antibodies: glial fibrillary acidic protein (GFAP) for astrocytes, O4, 
galactocerebroside (GalC), and myelin basic protein (MBP) for oligodendrocytes 
and F4/80-antigen for microglial cells. All three glial cell types were detected in the 
cultures. Subset of the primary glial cells showed immunopositivity for Dap12 and 
Trem2. Double staining showed co-localization of Dap12 and Trem2 in the same 
cells with F4/80-antigen. However, not all cells positive for F4/80-antigen expressed 
Dap12 or Trem2, and Dap12 and Trem2 staining was also observed in cells negative 
for F4/80-antigen.  
We also prepared separate glial cell cultures. Microglial cells, oligodendrocytes and 
astrocytes can be separated by their different adhesion properties (McCarthy and de 
Vellis 1980; Cole R 1990). Mixed glial cell cultures were grown for two weeks and 
 50 
microglial cells and oligodendrocyte progenitors then separated by shaking. 
Oligodendrocyte progenitors were proliferated and differentiated into mature 
oligodendrocytes. Microglial cells were obtained in high amounts and the cultures 
contained >95% F4/80 positive cells (Fig. 4A in I). These cells positively stained 
with Dap12 and Trem2 specific antibodies (Fig. 10A), but not with Trem2 0-serum 
(Fig. 4A in I). Oligodendrocytes were obtained in much lower numbers. They 
stained with the markers: O4, GalC and MBP (Fig. 4A in I). Oligodendrocytes too, 
showed expression of Dap12 and Trem2 proteins (Fig. 4B in I). Dap12 and Trem2 
proteins were additionally shown to co-localize in the same cell in both microglia 
and oligodendrocytes (Fig. 4B in I). Also in line with the RT-PCR analysis, separate 
primary cultures of mouse neurons showed no staining with the Dap12 antibody, but 
weak staining with the Trem2 antiserum. No expression was detected with either 
antibody in separate cultures of astrocytes. Thus we concluded that microglia and 
oligodendrocytes are the main Dap12 and Trem2 expressing cell types of the CNS. 
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Figure 10. Dap12 and Trem2 expression in glial cells. Microglial cells stained with 
F4/80 and Dap12 and Trem2 antibodies (A). Dap12 (B, lanes 1-5) and 
Trem2 (B, lanes 6-10) expression is detected in cerebral cortex (lanes 1 and 
6) and mixed glial cultures (lanes 4 and 9). Trem2 expression was also 
detected in neuronal cultures (lanes 7 and 8), but Dap12 was not (lanes 2 
and 3). Lanes 5 and 10 are negative controls. Rat primary cultures of 
microglia and oligodendrocytes showed Dap12 and Trem2 expression in RT-
PCR, whereas astrocytes did not (C). 
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5.2 Transcript profiles of DAP12/TREM2 deficient dendritic cells 
point to defects in actin bundling and immune response 
In the second part of the study we identified biological processes affected by lack of 
function of DAP12 and TREM2 in PLOSL patient dendritic cells (II). 
5.2.1 In vitro differentiated DCs and macrophages express DAP12 and 
TREM2  
We first isolated peripheral blood mononuclear cells (PBMC) of normal blood 
donors, enriched monocytes from them, and differentiated them into immature DCs 
and macrophages. Cells were collected after one, three, or seven days of 
differentiation with GM-CSF and IL-4 for DCs or GM-CSF for macrophages. 
Northern blot analysis revealed constitutive DAP12 mRNA expression in monocytes 
and throughout the differentiation process. TREM2 expression was detected at days 
three and seven, when the cells were already committed for DC or macrophage 
differentiation (Fig. 1 in II).  
5.2.2 DAP12 and TREM2 deficient monocytes differentiate into DCs 
that respond to microbial stimuli 
In order to identify biological processes involved in the pathogenesis of PLOSL, we 
studied PBMC of PLOSL patients lacking functional DAP12 or TREM2. Blood 
samples from five PLOSL patients were obtained. Three of the patients were 
homozygotes for the PLOSLFin mutation (deletion of exons 1-4 of TYROBP; Paloneva 
et al. 2000), and two of the patients were homozygotes for point mutations in TREM2, 
one resulting in a premature stop codon (Q33Stp) and the other leading to an amino 
acid substitution (V126G) (Paloneva et al. 2002, Klunemann et al. 2005). 
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We isolated PBMC from the PLOSL patients as well as from healthy donors, 
enriched monocytes by adherence, and differentiated them into DCs. In order to 
determine whether DAP12 and TREM2 deficient cells differentiate into immature 
DCs, the cells were stained with antibodies specific for surface marker proteins of 
immature DCs and the expression was monitored by flow cytometry. DAP12 and 
TREM2 deficient cells expressed the immature DC surface markers CD1a, CD86, 
and HLA class II molecules. Although there was slight variation in CD1a and CD86, 
the expression levels did not differ significantly from the levels detected in control 
cells (Fig. 2 in II). The immature DC character was further proven by the absence of 
the monocyte marker CD14 and the mature DC marker CD83 on both, DAP12 and 
TREM2 deficient cells. Thus we concluded that DAP12 and TREM2 deficient cells 
have the capacity to differentiate into immature DCs in vitro. 
DCs are the sentinels for foreign antigens in peripheral tissues. When immature DCs 
come in contact with microbes or their components, they mature into professional 
antigen presenting cells (APCs) that produce multiple cytokines and express cell 
surface molecules important for their proper function (Cella et al. 1997). We tested 
whether DAP12 and TREM2 deficient DCs can respond to microbial stimuli using 
lipopolysaccharide (LPS) and Sendai virus. It has been demonstrated that in human 
DCs TREM2 is effectively downregulated within 24 hours after LPS stimulation 
(Bouchon et al. 2001b). Consistent with this, our in vitro differentiated DCs from 
normal blood donors showed a strong downregulation of TREM2 transcript within 
12 hours after LPS stimulation (Fig. 4 in II). DAP12 expression was not affected for 
up to 24 hours after LPS treatment.  
We stimulated the DAP12 and TREM2 deficient DCs as well as control DCs with 
LPS or Sendai virus for 24 hours. CD86 and HLA class II expression were 
determined by flow cytometry before and after LPS and Sendai virus stimulation. 
We also monitored the ability of DAP12 and TREM2 deficient DCs to produce 
different cytokines in response to LPS and Sendai virus. The production of the pro-
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inflammatory cytokines TNF-α and IL-12, the anti-inflammatory cytokine IL-10, 
and the chemotactic molecules CCL2 (MCP-1), CCL19 and CXCL10 (IP-10) were 
determined in cell culture supernatants collected at 24 hours after LPS stimulation or 
Sendai virus infection. Altogether DAP12 and TREM2 deficient cells responded to 
LPS and Sendai virus stimulation very similarly to control cells (Fig. 5 in II). The 
major differences observed were that LPS-induced expression of CD86 was reduced 
in DAP12 and TREM2 deficient DCs and the DAP12 deficient DCs produced no 
TNF-α in response to LPS. 
5.2.3 DAP12 and TREM2 deficient DCs show morphological changes 
We have previously shown that actin ring formation is disturbed in in vitro 
differentiated osteoclasts from DAP12 and TREM2 deficient patients (Paloneva et 
al. 2003). In order to visualize the actin cytoskeleton of the DAP12 and TREM2 
deficient DCs, the DCs were centrifuged on microscope slides and stained with 
fluorescent phalloidin, which binds to F-actin in the cells. Confocal microscopy 
revealed that the DAP12 and TREM2 deficient DCs have more processes than 
control DCs (Fig. 11).  
We measured the surface areas (μm2) of DCs of two control individuals (number of 
cells, n=30 and 35), one DAP12 deficient individual (n=30), and one TREM2 
deficient individual (n=46). Phalloidin stained cells were scanned with confocal 
microscope and the surface areas determined with the microscope’s software. 
Statistical analysis showed that the mean surface areas of both DAP12 deficient DCs 
and TREM2 deficient DCs were larger than those of control DCs (Mann-Whitney 
U-test, p<0.0001). The difference in surface area is likely to result from the 
increased number of processes of the DAP12 and TREM2 deficient cells.  
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Figure 11.  DAP12 and TREM2 deficient DCs show morphological changes when 
stained with fluorescent phalloidin for F-actin. 
 
5.2.4 Transcript profiles of PLOSL DCs versus control DCs reveal 
differential gene expression 
We analyzed the transcript profiles of DCs of PLOSL patients and control 
individuals with Affymetrix microarrays. DCs were collected at day seven of GM-
CSF and IL-4 stimulated differentiation. Total cellular RNAs of DCs of three 
controls, three DAP12 deficient individuals, and two TREM2 deficient individuals 
were hybridized to the Affymetrix HG-U133A GeneChip probe arrays individually. 
The data was analyzed with the Genespring 7.1 software. After data processing and 
quality control, the initial 22 283 probe sets were reduced to 7 606. Due to the 
limited number of patient samples we analyzed the DAP12 and TREM2 deficient 
samples as one group to look for differences between PLOSL and controls. We 
performed iterative pathway analysis on the 7 606 probe sets, separately for the 
down- and upregulated genes. The downregulated transcripts showed enrichment for 
four Gene Ontology (GO) biological process classes (Fig. 12, Table 1 in II): 
inflammatory response, innate immune response, chemotaxis, and actin filament 
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bundle formation. The upregulated transcripts were enriched for ten GO biological 
processes: inflammatory response, innate immune response, chemotaxis, 
complement activation (classical pathway), lymphocyte activation, cell-cell 
signaling, calcium ion homeostasis, negative regulation of cell proliferation, 
cytoplasmic sequestering of NF-κB, and pyridine nucleotide metabolism.  
 
 
Figure 12. Pathways of actin bundling and immune response are regulated in PLOSL 
DCs. Downregulated pathways are shown in white, upregulated in grey.  
We further analyzed a subset of the differentially expressed genes by quantitative 
real-time PCR to validate the results obtained by the microarray analysis. The 
expression levels of three downregulated genes (SPP1, NEDD9, and FSCN1) and 
three upregulated genes (CCL2, BCL3, and NFKBIA) were analyzed with RT-PCR 
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from three controls, three DAP12 deficient samples and two TREM2 deficient 
samples (Table 3 in II). Changes in FSCN1 and NFKBIA transcript levels were seen 
between DAP12 mutants and controls, but not between TREM2 mutants and 
controls. The fold changes of the upregulated genes, CCL2 and BCL3, were lower 
and the fold changes of the downregulated genes, SPP1 and NEDD9, were higher 
when analyzed with RT-PCR as compared to the array hybridization. 
5.3 Dap12 deficient mice show altered synaptic transcripts and 
defects in microglial function 
In the third part of the study (III) we identified changes in expression of synaptic 
and myelin transcripts in the brain of Dap12 deficient mice and analyzed the 
functionality of Dap12 knockout microglia. 
5.3.1 Dap12 knockout mice show increased expression of synaptic and 
myelin associated transcripts 
The Dap12 knockout mice used in this study were originally produced at the 
laboratory of Dr. Lewis Lanier in University of California San Francisco (Bakker et 
al. 2000). The mice lack the exons three and four of the Tyrobp gene. In order to 
analyze the effect of the Dap12 mutation on the central nervous system of the mice, 
we performed genome wide expression analysis of the diencephalon and basal 
ganglia, the brain areas where most dramatic PLOSL pathology has been described, 
of a month old Dap12 mutant mice. RNA from the brain of three heterozygous 
control and three homozygous male mice were hybridised to the Affymetrix 
Mouse430_2 probe arrays individually. The data was analyzed with the GeneSpring 
GX7.3 software. Genes that passed the quality control were then ranked according to 
their expression fold change, separately for up- and downregulated genes, and 
subjected to the iterative pathway analysis. Several pathways involved in synaptic 
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function were significantly up-regulated in Dap12 knockout mice (Fig. 1 and Table 
1 in III). Among the up-regulated genes were also five myelin related genes: myelin-
associated oligodendrocytic basic protein (Mobp), myelin basic protein (Mbp), 
myelin proteolipid protein (Plp1), myelin and lymphocyte protein (Mal), and cyclic 
nucleotide phosphodiesterase 1 (Cnp1). The two down-regulated pathways were 
involved in regulation of development. 
5.3.2 Differential gene expression in Dap12 knockout microglia 
In the first part of the study we showed that microglia express both Dap12 and 
Trem2 (I). As the CNS is a very heterogeneous tissue we were looking to reduce the 
complexity and in addition to brain tissue analyzed the transcript profiles of primary 
microglia. RNA isolated from three Dap12 deficient and three wild type microglial 
cell cultures were hybridised to the Affymetrix Mouse430_2 probe arrays 
individually. The data were analyzed with GeneSpring and biological associations 
were assigned to differentially expressed genes with the Webgestalt tool. Several 
pathways were differentially regulated between Dap12 knockout and wild type 
microglia (Fig. 3 and Table 2 in III).  
5.3.3 Dap12 knockout microglia show decreased survival and migration 
as well as morphological changes in vitro 
It has been shown that the DAP12/TREM2 receptor complex promotes survival of 
human in vitro induced dendritic cells (Bouchon et al. 2001b). We studied the 
survival of Dap12 deficient microglia. We plated 15 000 Dap12 knockout and wild 
type cells per well and assayed them at day one, three, and five after plating with the 
CellTiter 96® Aqueous One Solution reagent that measures the amount of living 
cells in a well. At day one, the measured absorbance at 490 nm was about the same 
for both genotypes. At days three and five the absorbance was considerably higher 
for the wild type cells than Dap12 knockouts indicating greater amount of living 
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cells. The absorbance remained constant throughout the course of the experiment for 
the wild type cells, but decreased considerably from day one to day three for the 
Dap12 knockout cells (Fig. 4 in III). This indicates that the Dap12 knockout cells 
start dying in culture before day three and Dap12 is needed for the survival of 
microglia. 
To study the migratory capacity of the cells, we plated Dap12 knockout and wild 
type microglia on polyester membrane inserts in Transwell 96 well plates at 25 000 
cells per well. Migration of microglia through the membranes was assessed 24 hours 
after plating. The number of cells that had migrated through the membrane and 
attached to the bottom of the wells was counted. The number of wild type microglia 
that had passed through the membrane was 1.4 fold greater (n=10, p<0.05, Fig. 7 in 
III) than that of the Dap12 knockout microglia indicating a defect in the migratory 
capacity of the knockout microglia.  
We have shown that DAP12 deficient in vitro induced human dendritic cells and 
osteoclasts show morphological changes and abnormal F-actin distribution 
compared to control cells (II, (Paloneva et al. 2003)). To look at the morphology of 
the Dap12 knockout microglia in vitro, we fixed them at day one after shaking and 
stained them with the myeloid marker F4/80 as well as fluorescently labelled 
phalloidin for F-actin. Dap12 knockout primary microglia showed different 
morphology and altered F-actin distribution compared to the wild type microglia 
(Fig. 13 and Fig.5 in III).  In culture, the wild type microglia (Fig.5 A&C in III) 
have an elongated morphology and a number of processes whereas the Dap12 
knockout microglia (Fig.5 B&D in III) are more round with less processes. 
Activated microglia retract their processes and show ameboid morphology (Haynes 
et al. 2006). We also performed immunohistochemical staining of Dap12 knockout 
and heterozygous mice brain with the microglial marker Iba1. We did not observe 
gross abnormalities in the morphology of the Dap12 knockout microglia in vivo 
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(Fig. 13). Dap12 thus seems to influence the activation status of the microglia, at 
least in vitro. 
 
 
Figure 13.  Morphology of microglia in vitro and in vivo. Wild type (A) and Dap12 
knockout (B) primary microglia stained with the F4/80 antibody. Dap12 
heterozygote (C) and knockout (D) brain slices stained with Iba-1. Pictures 
are from caudate-putamen of one month old mice. 
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5.3.4 Primary oligodendrocytes can be cultured from Dap12 deficient 
mice 
It has been suggested that oligodendrocyte differentiation is impaired in the Dap12 
knockout mice (Kaifu et al. 2003; Nataf et al. 2005). We cultured oligodendrocytes 
from Dap12 knockout as well as wild type mice. Mixed glial cell cultures were first 
grown for two weeks and oligodendrocyte progenitors then separated by shaking. 
Oligodendrocyte progenitors were proliferated and differentiated into mature 
oligodendrocytes. We did not observe differences in the differentiation process of 
wild type and Dap12 knockout oligodendrocytes (Fig. 14). 
 
 
Figure 14. Oligodendrocytes cultured from wild type and Dap12 knockout mice. The 
cells were stained with the oligodendrocyte marker O4 antibodies. 
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6 DISCUSSION 
6.1 Dap12 and Trem2 expression in the CNS 
In this study, Dap12 and Trem2 expression was detected in the mouse CNS already 
at the embryonic stage and the steady state expression levels did not change 
significantly during development. Dap12 and Trem2 transcripts were expressed in 
the same brain regions with similar distributions. Furthermore, Dap12 and Trem2 
transcripts and proteins were detected in primary cultures of microglial cells and 
oligodendrocytes. Astrocytes did not show any Dap12 or Trem2 expression. 
Neurons showed no Dap12 and only little Trem2 expression in vitro (I). Other 
studies have also been conducted on Dap12 and Trem2 expression in the CNS. 
Dap12 mRNA and protein expression have been detected in cultured microglia and 
oligodendrocytes (Kaifu et al. 2003). Trem2 transcripts have been detected in mouse 
microglia both in vitro and in vivo (Schmid et al. 2002). Roumier et al detected 
Dap12 protein expression only in mouse microglia and not in neurons, astrocytes, or 
oligodendrocytes in mixed glial cultures and in vivo (Roumier et al. 2004). 
Similarly, Trem2 protein expression was detected in primary microglia, but not in 
astrocytes, oligodendrocytes, or neurons (Takahashi et al. 2005). In contrast, Sessa 
et al. detected Dap12 and Trem2 expression in human and mouse neurons in 
addition to microglia in vivo (Sessa et al. 2004). All of these studies have found 
Dap12 and Trem2 expression in microglia. Thus the expression of Dap12/Trem2 
complex in microglial cells is well established, but there are contradictory results on 
whether other CNS cell types also express them. One of the possible explanations is 
that Dap12 and Trem2 expression might be induced in culture even in cells that do 
not express them in vivo.  Another explanation could be that Dap12 and Trem2 are 
expressed at a specific time point during oligodendrocyte differentiation or induced 
in response to some specific environmental cues. 
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6.2 DAP12/TREM2 deficient DCs 
TREM2 was originally described as a receptor that forms an activating complex 
with DAP12 in human in vitro differentiated immature DCs (Bouchon et al. 2000; 
Bouchon et al. 2001b). Our genome wide expression analysis of DAP12 and 
TREM2 deficient DCs showed differential expression of transcripts with biological 
functions well in agreement with previously reported functions of the 
DAP12/TREM2 receptor complex (II). DAP12 and TREM2 have been implicated in 
triggering and controlling inflammatory responses (Lanier et al. 1998; Bouchon et 
al. 2001b) as well as regulating chemotaxis (Takahashi et al. 2005). Accordingly, 
our analysis showed up- and down regulation of transcripts involved in 
inflammatory response, innate immune response, and chemotaxis. Ligation of 
TREM2 on DCs has been shown to result in an increase in intracellular calcium 
concentration, increased survival, and decreased proliferation of DCs (Bouchon et 
al. 2001b). The genes for cell-cell signaling, calcium ion homeostasis, and negative 
regulation of cell proliferation were upregulated in our expression analysis of 
DAP12/TREM2 deficient patient DCs. It is likely that other proteins, involved in 
signal transduction and calcium ion homeostasis are able to compensate for the 
missing DAP12/TREM2 signalling, since the DCs obtained from PLOSL patients 
can respond to microbial stimuli and the patients do not manifest major 
immunological problems.  
We observed certain interesting differences in the response of the DAP12/TREM2 
deficient DCs to microbial stimuli compared to control DCs. First, LPS-induced 
expression of CD86 in DAP12/TREM2 deficient cells was reduced. In agreement 
with our data, LPS-induced expression of CD86 in myeloid DCs was also found 
deficient in DAP12 knockout mice (Terme et al. 2004). Similarly, like our DAP12 
deficient patient cells, DAP12 deficient mouse DCs produced reduced amounts of 
TNF-α in response to LPS stimulation (Hamerman et al. 2005). It was thus proposed 
that DAP12 mediated signals regulate signaling via Toll-like receptors (TLRs) 
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(Hamerman et al. 2005; Turnbull et al. 2005). TLR signalling results in NF-κB 
activation (Akira and Takeda 2004). Our microarray data showed upregulation of 
transcripts for cytoplasmic sequestering of NF-κB in DAP12/TREM2 deficient cells. 
The upregulated genes: BCL3 and NFKBIA encode inhibitors of NF-κB (Wulczyn 
et al. 1992; Hoffmann et al. 2002). Thus, our findings support the hypothesis that 
DAP12/TREM2-mediated signaling may influence on TLR signaling and suggests 
that the effect may be mediated via inhibition of NF-κB. 
6.3 Microglia in neurodegeneration 
Others and we have shown that microglia express Dap12 and Trem2 (I, (Takahashi 
et al. 2005)). Since DAP12 and TREM2 were initially identified in cells of the 
immune system, it is not surprising to find them in these cells that share the same 
lineage of origin.  Microglial cells are the resident immune cells of the CNS (Aloisi 
2001). They are found in all brain regions and comprise between 5 and 15% of cells 
in the CNS (Schmid et al. 2002). Their activation is characteristic to most 
neurodegenerative diseases (Woodroofe et al. 1986; Dickson et al. 1993; Morioka et 
al. 1993; Lenzlinger et al. 2001; Vila et al. 2001; Carson 2002). Activation of 
microglia has also been demonstrated in autopsied PLOSL brain (Paloneva et al. 
2001). Still, the role of microglial activation in neurodegeneration is complicated 
and unclear. Release of proinflammatory and cytotoxic factors by microglia have 
been suggested to contribute to neurodegeneration (Chao et al. 1992; Lee et al. 
1993). On the other hand, microglia can have proregenerative and neuroprotective 
functions as injured neurons recover from injury when activated microglial cells are 
present (Streit 2002). Microglial cells also produce neuroprotective agents and 
scavenge for cellular debris resulting from injury or disease (Imai and Kohsaka 
2002). Consequently, it has been suggested that neurodegeneration might not result 
primarily from microglial aggression, but rather from neglect by these cells (Streit 
2002). The type of signals mediated by the Dap12/Trem2 complex in microglia is 
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currently unknown. The DAP12/TREM2 complex was initially found to transduce 
activating signals in DCs (Bouchon et al. 2001b). By contrast, it was recently shown 
that the Dap12/Trem2  complex transduces inhibitory signals in macrophages 
(Hamerman et al. 2006; Turnbull et al. 2006). There is some evidence that the 
Dap12/Trem2 complex would have an inhibitory role also in microglia. Our Dap12 
deficient microglia had more activated morphology than wild type microglia (III). 
Trem2 signalling in microglia downregulates inflammation, since Trem2 
knockdown microglial cells have been shown to express increased amounts of the 
proinflammatory transcripts TNF-α, IL-1β and NOS2 (Takahashi et al. 2005).  
Further characterization of the downstream effects of Dap12/Trem2 mediated signal 
transduction in microglia will be needed to solve this issue. 
In response to demyelination, microglia are able to proliferate, migrate into 
demyelinated areas and present antigen (Remington et al. 2007). Following injury, 
microglia migrate or extend processes toward sites of tissue damage (Nimmerjahn et 
al. 2005; Haynes et al. 2006). One of the pre-requisites for cell migration or process 
extension is reorganization of the actin cytoskeleton (Vicente-Manzanares and 
Sanchez-Madrid 2004). The in vitro induced DAP12/TREM2 deficient dendritic 
cells in this study showed abnormal actin staining pattern and more cellular 
processes than control cells as well as downregulation of transcripts involved in 
actin filament bundle formation (II). This observation is well in line with previous 
findings of abnormal actin staining pattern in DAP12/TREM2 deficient osteoclasts, 
also induced in vitro (Cella et al. 2003; Paloneva et al. 2003). We observed that F-
actin distribution in Dap12 deficient microglia differed from that in wild type 
microglia. It has earlier been demonstrated that crosslinking of Trem2 on microglia 
leads to polarization and reorganization of F-actin (Takahashi et al. 2005). We saw 
downregulation of transcripts involved in cell migration in the expression analysis 
and decreased migration through the membranes in our migration assay by Dap12 
deficient microglia. In line with our results, it has been shown that Trem2 
stimulation in microglia increased migratory activity of microglia (Takahashi et al. 
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2005). We also noted that Dap12 microglia do not survive in culture for as long as 
wild type microglia. It has earlier been shown that the DAP12/TREM2 receptor 
complex promotes survival of human dendritic cells (Bouchon et al. 2001b). Also, 
genes involved in negative regulation of cell proliferation were upregulated in our 
expression analysis of the patient DCs (II). Our results add to the evidence that 
Dap12 plays a role in microglial migration and survival/proliferation, both of which 
are important properties for the response of these cells to CNS damage such as 
demyelination. 
6.4 Loss-of-myelin in PLOSL 
The most prominent feature of PLOSL is the loss-of-myelin in the brain. We saw 
differential expression of myelin components (Mobp, Mbp, Plp, Mal, and Cnp1) in 
our expression analysis of Dap12 knockout mouse brain. It has been demonstrated 
that Dap12 deficient mice develop thalamus accentuated hypomyelinosis and show 
reduction in the number of myelinated axons in electron microscopy of the thalami 
(Kaifu et al. 2003). In histological analysis, Nataf et al. also observed diffuse 
hypomyelination predominating in anterior brain regions not accompanied with 
oligodendrocyte degeneration or microglial activation in Dap12 mutant mice (Nataf 
et al. 2005). Although we did not observe changes in Mbp staining in 
immunohistochemistry, electron microscopy might reveal similar changes also in the 
mice used in this study. Upregulation of the transcripts for myelin components 
might reflect a trial to compensate for the loss-of-myelin. It has been suggested that 
the hypomyelination is due to developmental arrest of oligodendrocytes (Kaifu et al. 
2003) or developmental defect of myelin formation (Nataf et al. 2005). Our results 
do not support this hypothesis, since we did not notice differences in primary 
oligodendrocyte differentiation from Dap12 deficient and wild type mice (III).  
Myelin loss also occurs in the human disease multiple sclerosis (MS). Experimental 
autoimmune encephalomyelitis (EAE) is studied as an animal model of MS. It has 
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recently been demonstrated that blocking Trem2 with an antibody at the onset of 
MOG35-55 induced EAE worsens the disease outcome (Piccio et al. 2007). It was 
also shown that Trem2-transduced bone marrow derived myeloid cells (BM-MC) 
that were injected (i.v.) into mice at the peak of EAE, migrated into the CNS lesions, 
induced clearance of myelin debris, and created an anti-inflammatory cytokine 
environment. Mice injected with the Trem2 transduced BM-MC showed less axonal 
injury and demyelination than mice injected with GFP transduced BM-MC 
(Takahashi et al. 2007). The myelin loss observed in PLOSL could also be due to an 
impaired support function of the Dap12/Trem2 deficient myeloid cells.  
6.5 Synaptic defects in PLOSL 
The Dap12 deficient mice used in this study do not show any gross abnormalities in 
their CNS. We were interested to find out whether they show changes in the 
molecular level that would give us clues to the CNS pathogenesis of PLOSL. In the 
genome wide expression analysis we observed changes in expression of many 
transcripts and saw regulation of specific biological pathways. Most of the 
differentially expressed pathways in Dap12 deficient mouse brain were involved in 
synaptic function. Synaptic function has been shown to be impaired in the other two 
Dap12 mutant mice (Kaifu et al. 2003; Roumier et al. 2004). Dap12 deficient mice 
described by Kaifu et al. (Kaifu et al. 2003) showed synaptic degeneration, reduced 
startle response, impaired prepulse inhibition to acoustic stimuli, and aberrant γ-
aminobutyric acid (GABA) receptor mediated miniature inhibitory postsynaptic 
currents (mIPSCs) in the thalamus. Roumier et al. (Roumier et al. 2004) noted that 
in the Dap12 loss-of-function mutant mice long-term potentiation (LTP) was 
enhanced. They concluded that by affecting LTP Dap12 deficiency impacts on 
hippocampal synaptic plasticity. They also observed changes in synaptic receptor 
content by electrophysiology and biochemical analysis. The expression levels of the 
glutamate receptor GluR2 and the brain derived neurotrophic factor (BDNF) 
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tyrosine kinase receptor B (TrkB) in the whole cell level were not affected, but there 
was impairment of the synaptic accumulation of these receptors in the Dap12 
deficient mice (Roumier et al. 2004). In line with these previous findings, our 
genome wide expression analysis of Dap12 deficient thalami showed up-regulation 
of transcripts involved in protein trafficking into synapses and GABA mediated 
synaptic transmission. In addition to GABA receptor transcripts, transcript for 
Kcnq2 was highly up-regulated (14 fold). Kcnq2 is a potassium channel protein that 
modulates GABA release (Martire et al. 2004). In humans, Kcnq2 mutations are 
associated with an inherited epilepsy syndrome (Singh et al. 1998), which is of 
interest since PLOSL patients also suffer from epileptic seizures. 
Microglia are able to control developmental apoptosis and synaptogenesis and affect 
synaptic function (Bessis et al. 2007). Overt nitric oxide (NO) production by 
activated microglia has been shown to block transport of synaptic vesicle precursors, 
influence axonal transport of synaptotagmin and synaptic properties (Stagi et al. 
2005). We saw up-regulation of transcripts involved in NO metabolism and 
biosynthesis in Dap12 knockout microglia.  We also saw upregulation of transcripts 
involved in vesicle-mediated transport and synaptic vesicle membrane in Dap12 
knockout brain. One of the transcripts belonging to these categories was 
synaptotagmin (8 fold up). It has been suggested that microglial Dap12 affects 
synaptic function and plasticity through a microglia-neuron interaction, where 
microlial cells regulate synapse maturation and plasticity by secreting soluble factors 
(Roumier et al. 2004). In our study, we also observed changes in synaptic transcripts 
without clear CNS damage, but with functional defects of microglia in Dap12 
knockout mice (III). 
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6.6 Hypothesis of PLOSL pathogenesis 
The spatial expression patterns of Dap12 and Trem2 in the mouse CNS are in line 
with the pathological findings in PLOSL patients. Patients with PLOSL, who lack 
functional DAP12 or TREM2, suffer from a dramatic loss of CNS white matter. 
Loss-of-myelin is most prominent in the deep frontal and temporal white matter 
(Paloneva et al. 2001) and is of late onset. In addition, Dap12 knockout mice have 
been shown to suffer from hypomyelinosis (Kaifu et al. 2003; Nataf et al. 2005). 
Still, no developmental defects have been described in PLOSL patients or Dap12 
knockout mice. So, it seems that even though Dap12 and Trem2 are already 
expressed at the embryonic stage, they are not essential for normal CNS 
development, but rather for homeostasis of the adult CNS. Since myelin 
development seems not to be impaired in PLOSL patients, DAP12/TREM2 
signaling could be important in maintenance of the myelin sheath or remyelination. 
The capacity of CNS to repair demyelinating damage decreases with age (Ibanez et 
al. 2003). This might partially explain the late onset of PLOSL. In line with this, the 
skeletal system in PLOSL patients develops normally and the pathological changes 
manifest only at early adulthood (Hakola 1972).  
It has been shown that expression of Trem2 by microglia in healthy CNS varies 
between and within brain regions. So, not all microglia express Trem2. It has been 
suggested that different subsets of microglia are specialized to respond to defined 
extracellular signals, and regional variation in Trem2 expression may contribute to 
the varying sensitivities of different brain regions to similar pathological signals 
(Schmid et al. 2002). This might contribute to the different degrees of damage in 
different parts of the CNS in PLOSL. 
Concerning the clinical symptoms in PLOSL, it is also interesting, that we saw 
differential expression of SPP1 (secreted phosphoprotein 1) and CCL2 (c-c 
chemokine ligand 2/monocyte chemotactic protein 1 (MCP-1)) in PLOSL patients’ 
DCs. The donwregulated SPP1, also known as osteopontin, functions in the immune 
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system, but is also important for normal development and function of osteoclasts. It 
has been demonstrated that in human cells, reduced expression of osteopontin at 
early times of differentiation leads to a defect in osteoclastogenesis in vitro (Aitken 
et al. 2004). Further, osteopontin transcripts are increased in brain samples of 
multiple sclerosis (MS) patients (Chabas et al. 2001). The mRNA level of CCL2 
was highly upregulated in patients’ DCs. Increased CNS or cerebrospinal fluid 
(CSF) levels of CCL2 have been reported in chronic neurological disorders such as 
Alzheimer’s disease (Ishizuka et al. 1997), HIV-associated dementia (Kelder et al. 
1998), amyotrophic lateral sclerosis (ALS) (Wilms et al. 2003) and MS (Simpson et 
al. 1998). Further, transgenic mice overexpressing CCL2 develop late (>6 months) 
onset encephalopathy with mild perivascular leukocyte infiltration, impaired blood 
brain barrier function, and increased numbers of microglia with morphological 
features of activation (Huang et al. 2005). These findings of altered steady state 
levels of these two transcripts provide biological links with the pathology of both, 
brain and bone, characteristic to PLOSL.  
Loss of function of DAP12 or TREM2 affects specific biological pathways, 
especially those involved in actin remodelling, cell migration, cytokine production, 
and synaptic function. DAP12/TREM2 mediated signalling obviously plays an 
important role in the CNS, since its failure leads to PLOSL with severe CNS 
manifestations. Synaptic defects have been proposed to account for the early onset 
of some dementias (Terry and Katzman 2001; Selkoe 2002). It is not known whether 
the myelin loss in PLOSL causes the degeneration of the synapses or whether the 
synapses degenerate even before the loss-of-myelin. Microglia can affect both of 
these processes: myelin stability and synaptic function. In light of this study, it 
seems likely that, the primary defect in PLOSL would be in the communication of 
the microglia with their surroundings, in such a way that loss of the inhibitory 
Dap12/Trem2 signaling would lead to increased cytokine production and decreased 
migration by the microglia (Fig. 15). This would then disturb the CNS homeostasis 
and lead to the synaptic dysfunction and loss-of-myelin observed in PLOSL. 
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It would also be interesting to know if PLOSL patients would benefit from bone 
marrow transplantation. It has been shown that, at least in mice, bone marrow stem 
cells can migrate into the CNS and differentiate into microglia also in adulthood 
(Simard and Rivest 2004). It has also been shown that blood-derived microglia have 
the ability to eliminate amyloid deposits in a mouse model of Alzheimer’s disease 
(Simard et al. 2006). Since the Dap12 deficient mice do not reproduce the drastic 
CNS damage observed in PLOSL and the bone phenotype is quite the opposite, 
better animal models would be needed to test this hypothesis. Hopefully the Trem2 
knockout mice currently being generated in our laboratory will further contribute 
into better understanding of the CNS damage behind PLOSL. 
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Figure 15. Hypothesis of molecular events resulting in PLOSL. 
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7 CONCLUSIONS 
In this thesis work microglia and oligodendrocytes were identified as the Dap12 and 
Trem2 expressing cells of the CNS. In light of other studies on Dap12 and Trem2 
expression in the CNS published during this thesis work, there is increasing 
evidence that microglia are the cell type responsible for the CNS manifestations of 
PLOSL. When this study was undertaken, the DAP12/TREM2 complex was 
generally thought to transduce activating signals into cells (Bouchon et al. 2001b). 
During this work it has been shown that the DAP12/TREM2 complex can also 
transduce inhibitory signals (Hamerman et al. 2006; Turnbull et al. 2006). It now 
seems that the outcome of DAP12/TREM2 mediated signalling is dependent on the 
stimulating agent and the cell type in which the signalling occurs, which makes it 
important to further characterize the nature of the DAP12/TREM2 mediated signals 
in microglial cells. 
Specific biological processes are affected by lack of DAP12 and TREM2 in dendritic 
cells (DCs). Loss of Dap12 in mouse brain leads to changes in synaptic transcripts and 
transcripts of myelin components as well as functional defects in microglia. In both 
DCs and microglia, the DAP12/TREM2 signalling affects actin remodelling and 
survival/proliferation. In microglia it also affects cell migration. In addition to their 
role as immune cells, microglia can influence myelin stability and synaptic function. It 
is not known whether the myelin loss in PLOSL causes the degeneration of the 
synapses or whether the synapses degenerate even before the loss-of-myelin. Thus the 
exact role of DAP12/TREM2 mediated signalling in microglial communication with 
their surroundings warrants further study. Understanding how that works as well as 
identification of the TREM2 ligand and other DAP12/TREM2 interacting molecules 
will provide new insight into the pathogenesis of PLOSL and into the molecular 
pathogenesis of dementias more generally.  
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